新股消息 | 亦诺微医药港股IPO招股书失效

Group 1 - Immvira Bioscience Inc. submitted its Hong Kong IPO prospectus on June 25, which became invalid after six months on December 25, with Citigroup and CICC as joint sponsors [1] - The company focuses on clinical demand-driven biotechnology, aiming to discover, develop, produce, and commercialize novel oncolytic immunotherapies and engineered exosome therapies through proprietary biotechnological methods [2] - Immvira has designed a risk-balanced product portfolio that includes oncolytic immunotherapy candidates with best-in-class potential for treating solid tumors and innovative engineered exosome therapeutic products with clinical application prospects or direct commercialization potential [2]